Mineralys Therapeutics (NASDAQ: MLYS) holder plans 10,758-share stock sale

Rhea-AI Filing Summary

Mineralys Therapeutics stockholder Adam Levy has filed a notice to sell 10,758 shares of common stock through Merrill Lynch, with an aggregate market value of $345,722.93 on the NASDAQ. The filing notes 79,139,956 shares of common stock outstanding. The 10,758 shares to be sold were acquired on 01/10/2026 via vesting of a restricted stock unit award granted under the issuer’s equity compensation plan. Over the prior three months, Adam Levy sold 10,758 shares of common stock on 10/13/2025 for gross proceeds of $451,983.33 and 119,524 shares on 11/11/2025 for gross proceeds of $5,363,716.05.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	10758	345722.93	79139956	01/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/10/2026	Vesting of restricted stock unit award	Mineralys Therapeutics, Inc.			10758	01/10/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Adam Levy 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	10/13/2025	10758	451983.33
Adam Levy 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	11/11/2025	119524	5363716.05

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Mineralys Therapeutics (MLYS) disclose?

It discloses that Adam Levy plans to sell 10,758 shares of Mineralys Therapeutics common stock through Merrill Lynch, with an aggregate market value of $345,722.93 on the NASDAQ.

How many Mineralys Therapeutics (MLYS) shares are planned to be sold and on what date?

The notice covers 10,758 shares of Mineralys Therapeutics common stock, with an approximate sale date of 01/12/2026.

How did Adam Levy acquire the Mineralys Therapeutics (MLYS) shares being sold?

The 10,758 shares were acquired on 01/10/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan.

What prior sales by Adam Levy in Mineralys Therapeutics (MLYS) stock are disclosed?

In the past three months, Adam Levy sold 10,758 shares on 10/13/2025 for $451,983.33 and 119,524 shares on 11/11/2025 for $5,363,716.05 in gross proceeds.

How many Mineralys Therapeutics (MLYS) shares are outstanding according to the notice?

The notice states that there are 79,139,956 shares of Mineralys Therapeutics common stock outstanding.

Which broker is handling the planned Mineralys Therapeutics (MLYS) share sale?

The planned sale of 10,758 shares is to be executed through Merrill Lynch, located at 225 Liberty St, Floor 37, New York, NY 10281.